Literature DB >> 15787963

Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa-opioid receptor.

M J Przydzial1, I D Pogozheva, K E Bosse, S M Andrews, T A Tharp, J R Traynor, H I Mosberg.   

Abstract

A series of cyclic, disulfide- or dithioether-containing tetrapeptides based on previously reported potent mu- and delta-selective analogs has been explored with the aim of improving their poor affinity to the kappa-opioid receptor. Specifically targeted were modifications of tetrapeptide residues 3 and 4, as they presumably interact with residues from transmembrane helices 6 and 7 and extracellular loop 3 that differ among the three receptors. Accordingly, tetrapeptides were synthesized with Phe(3) replaced by aliphatic (Gly, Ala, Aib, Cha), basic (Lys, Arg, homo-Arg), or aromatic sides chains (Trp, Tyr, p-NH(2)Phe), and with d-Pen(4) replaced by d-Cys(4), and binding affinities to stably expressed mu-, delta-, and kappa-receptors were determined. In general, the resulting analogs failed to exhibit appreciable affinity for the kappa-receptor, with the exception of the tetrapeptide Tyr-c[d-Cys-Phe-d-Cys]-NH(2), cyclized via a disulfide bond, which demonstrated high binding affinity toward all opioid receptors (Ki(mu) = 1.26 nm, Ki(delta) = 16.1 nm, Ki(kappa) = 38.7 nm). Modeling of the kappa-receptor/ligand complex in the active state reveals that the receptor-binding pocket for residues 3 and 4 of the tetrapeptide ligands is smaller than that in the mu-receptor and requires, for optimal fit, that the tripeptide cycle of the ligand assume a higher energy conformation. The magnitude of this energy penalty depends on the nature of the fourth residue of the peptide (d-Pen or d-Cys) and correlates well with the observed kappa-receptor binding affinity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15787963     DOI: 10.1111/j.1399-3011.2005.00220.x

Source DB:  PubMed          Journal:  J Pept Res        ISSN: 1397-002X


  6 in total

1.  Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.

Authors:  Lauren C Purington; Katarzyna Sobczyk-Kojiro; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Biol       Date:  2011-10-11       Impact factor: 5.100

Review 2.  Homology modeling of opioid receptor-ligand complexes using experimental constraints.

Authors:  Irina D Pogozheva; Magdalena J Przydzial; Henry I Mosberg
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

3.  Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.

Authors:  Lauren C Purington; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

4.  Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models.

Authors:  Jessica P Anand; Lauren C Purington; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  Chem Biol Drug Des       Date:  2012-09-12       Impact factor: 2.817

5.  Conformation-opioid activity relationships of bicyclic guanidines from 3D similarity analysis.

Authors:  Karina Martínez-Mayorga; Jose L Medina-Franco; Marc A Giulianotti; Clemencia Pinilla; Colette T Dooley; Jon R Appel; Richard A Houghten
Journal:  Bioorg Med Chem       Date:  2008-04-27       Impact factor: 3.641

Review 6.  Cyclic Opioid Peptides.

Authors:  Michael Remesic; Yeon Sun Lee; Victor J Hruby
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.